Logo
x

Search

Subscribe Now

HES

AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES)

AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES)

  • April 4, 2019
AstraZeneca's Fasenra Receives Orphan Drug Designation (ODD) For Hypereosinophilic Syndrome (HES)

AstraZeneca's Fasenra Receives Orphan Drug Designation (ODD) For Hypereosinophilic Syndrome (HES)

  • February 7, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.